Cart
sales@molnova.com
Mast Cell Degranulating Peptide HR-2
CAS No. 80388-04-1
Mast Cell Degranulating Peptide HR-2( —— )
Catalog No. M30196 CAS No. 80388-04-1
Peptide from giant hornet Vespa orientalis that has biological effects similar to mast cell degranulating peptide from bee venom.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMast Cell Degranulating Peptide HR-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionPeptide from giant hornet Vespa orientalis that has biological effects similar to mast cell degranulating peptide from bee venom.
-
DescriptionPeptide from giant hornet Vespa orientalis that has biological effects similar to mast cell degranulating peptide from bee venom.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number80388-04-1
-
Formula Weight1523
-
Molecular FormulaC77H135N17O14
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:{Phe}{Leu}{Pro}{Leu}{Ile}{Leu}{Gly}{Lys}{Leu}{Val}{Lys}{Gly}{Leu}{Leu}-NH2
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Tu?chibaev MU, et al. [Low molecular weight peptides from the venom of the giant hornet Vespa orientalis. Structureand function]. Biokhimiia. 1988 Feb;53(2):219-26.
molnova catalog
related products
-
Ipilimumab
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
-
Cirsimaritin
Cirsimaritin exhibits antibacterial, anti-inflammation, anti-tumor, antioxidant properties and renal protection. Cirsimaritin binds weakly to the benzodiazepine site on GABAA receptors.
-
Nemvaleukin alfa
Nemvaleukin alfa (ALKS 4230) is an interleukin 2 fusion protein, a selective agonist of the medium-affinity IL-2 receptor, produced by fusion of the IL-2Ralpha subunit of the circularly arranged interleukin-2 (IL-2) and IL-2 receptor (IL-2R) complexes, which drives antitumor Immunity and inhibits tumor growth in small cell lung cancer.
